Roxi-AI is the life sciences industry’s first longitudinal, outcomes-linked risk signals database. Our predictive models uncover hidden patterns of success and failure – systematically de-risking portfolios and sharpening biopharma investment and development decisions.
Many of us who have spent our careers in the life sciences are keen to accelerate the time it takes to get much-needed therapies to market. We don’t want to keep patients waiting.
There are many ways to tackle the problem of selecting and de-risking therapeutic assets. At Roxi-AI, we have seen the inefficiency in this process as we’ve worked side by side with biopharma, clinical development service providers, and investors, de-risking assets and optimizing their profiles to increase commercial success. Every organization has its process, criteria, and a team of individuals to drive asset prioritization decisions. Sometimes, they get it right, but all too often, they don’t.
The consequences are lost time and money and patient frustration. It’s time to take the guesswork out of deciding which assets to keep, which ones to kill, and which to remediate to get on the right path.
Roxi-AI converts fragmented biopharma evidence into outcome-linked risk signals you can act on. We align time-stamped data, learn from historical clinical and regulatory results, and deliver explainable readouts at the asset and portfolio level.
Aggregate & align. Normalize trial, regulatory, mechanistic, safety, competitive, and commercial signals; time-stamp them and map to each asset’s development path.
Learn from outcomes. Train and validate explainable models against past approvals, halts, and regulatory guidance to separate early winners from likely failures—no black boxes.
Deliver actions. Provide catalyst windows, risk drivers, and scenario ranges—plus portfolio roll-ups and an Investor Committee -ready memo—with near real-time updates.
Result: faster conviction, systematic de-risking, and clearer calls you can defend.
Decisions deserve signals you can trust. We build for clarity, comparability, and real-world impact.
Outcome-linked signals grounded in clinical and regulatory results—not opinions.
A unified risk taxonomy and benchmarks so assets are compared apples-to-apples.
All relevant evidence in one view—clinical, regulatory, scientific, and market—time-stamped.
Explainable drivers, investor committee-ready memos, and agents that fit BD and R&D strategy workflows.
Our proprietary 100-point risk benchmarking system to evaluate assets and surface opportunities for de-riskign development plans.
Rigorously evaluates biopharma assets using a comprehensive risk assessment, graded on an AAA-D scale.
Compares the risk profiles of biopharma assets against industry benchmarks.
Simulate the impact of strategic design considerations on the likelihood of clinical, regulatory and market success of an asset.
Your own diligence agent trained on biopharma data and workflows
Our proprietary 100-point risk evaluation system to comprehensively assess various risks.
Rigorously evaluates biopharma assets using a comprehensive risk assessment, graded on an AAA-D scale
Compares the risk profiles of biopharma assets against industry benchmarks
Assess likelihood of commercial success for biopharma assets
biopharma deal marketplace, facilitating connections between biopharma companies and investors
Run a 72-hr focused, explainable review of a company or asset using outcome-linked risk signals—finish with an IC-ready memo.
On-demand signal snapshot with asset-level risk summaries, key drivers, and peer comparators—built for public-market decisions.
Map risks across your pipeline/portfolio, identify fixable issues, and benchmark against peers to prioritize capital and work.
Track peer assets, milestones, and risk shifts so your team sees inflection points before the market or the deal table.
An AI research copilot trained on life-sciences signals and sources—safe, explainable answers with citations your team can trust.
Proven patient and HCP centric-innovation models to drive cross-functional innovation.
Unlock potential across disconnected in-house and third party data sets.
Optimize pipeline and enable organization-wide synergies for early stage assets.
Prepare the market for successful product launches through medical affairs enablement.
Pricing, Go-to-market strategies, Predictive market risk mitigation.
At Roxi-AI, we streamline the complex process of biopharma asset evaluation through a series of precise, insightful steps. Our approach ensures you have the information and tools needed to make informed decisions with confidence.
By analyzing data from diverse sources, we offer detailed risk profiles and actionable recommendations, empowering you to navigate challenges effectively. Our commitment to precision and insight helps you make strategic, data-driven decisions that drive success and growth in the biopharma industry.
